Back to HerDesire.net Education and Resources
HSDD (Hypoactive Sexual Desire Disorder)
Front MatterWebcastDownload SlidesPostTest/Evaluation
Evaluating Outcomes of HSDD Treatment: Clinical Measures of Success:
A Clinicians and Patient's Perspective

with Sheryl Kingsberg, PhD, IF, Brooke M. Faught, MSN, WHNP-BC, IF and Amanda Blackie-Parrish, Patient

INTENDED AUDIENCE

OB/GYNs, urologists, primary care physicians, endocrinologists, nurses with focus in reproductive/sexual medicine, NPs/PAs, psychologists/sex therapists, residents/fellows of above disciplines, managed care clinicians, and clinical pharmacists interested in management and treatment of hypoactive sexual desire disorder (HSDD).

STATEMENT OF NEED

Sexual health is an integral component of women’s psychological and overall physical health. Clinicians often perceive the treatment of female sexual health as a quality of life issue and low health priority; furthermore, they often do not believe they possess the knowledge and experience to diagnose and manage HSDD. Even though HSDD significantly impairs their overall sense of well-being, sexual satisfaction, and the quality of their relationships, many patients do not bring up sexual health, due to embarrassment and lack of education on sexual health. Physicians often feel inadequately trained to directly address sexual health and unable to focus on patient concerns due to time-constraints. There is a clear need for education to help clinicians proactively speak to patients about sexual health concerns that patients may consider difficult to discuss, and to facilitate collaboration between specialists in various disciplines that manage women’s health.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity participants should be better able to:

  1. Collaborate, proactively discussing their female patients sexual wellbeing and needs, in a concerted effort to promote open and stress-free discussions with each other and their patients regarding the level of distress HSDD and sexual dysfunction has on each patient’s overall health and well-being
  2. Encourage each woman to engage in discussions of sexual health with her doctor, to determine "normal" sexual function and dysfunction for her
  3. Select appropriate treatment based on consensus Guidelines and FDA-approved options, patient’s treatment goals, and the degree to which the patient wants sexual function restored

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and CogniMed Inc. TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

TOPEC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTENT REVIEW STATEMENT

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of TOPEC Clinical Content Review Committee who has no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and balanced.

DISCLOSURE OF CONFLICTS OF INTEREST

In accordance with ACCME Standards for Commercial Support, TOPEC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

TOPEC
Sean Barrett has nothing to disclose.

CogniMed Inc
Jeffrey Rosenberg has nothing to disclose.

Faculty
Dr Sheryl Kingsberg is a consultant for Valeant, Emotional Brain, Pfizer, Shionogi, TherapeuticsMD, NovoNordisk, Nuelle, Masteron, Perrigo, Palatin and Actavis. She has been contracted for research by Palatin. She has stock options in Viveve.

Brooke Faught is a consultant for Female Health Company, Valeant, and Palatin. She has accepted fees for non-CME services from Shionogi, Actavis, and Valeant. She has been contracted for research by Epi24 USA LLC.

Amanda Parrish has nothing to disclose.

Off-label statement
Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of CogniMed Inc. or TOPEC. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive on the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely on the information contained within this educational activity.

Jointly provided by

This activity is supported by an independent educational grant provided by Sprout Pharmaceuticals.

Next to Webcast